Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
BRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.21 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)78.80K
Market Cap
$12.29M
Enterprise Value$7.19M
Total Cash (Recent Filing)$9.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 18, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding7,978,117
10 Day Avg. Volume24,780
30 Day Avg. Volume78,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue18.39
Enterprise Value/Gross Profit19.97
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$8.00Price Target Upside440.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Efficacy Of BRTX-100The data release shows a significant improvement in function and pain for patients, indicating a positive trend for the efficacy of BRTX-100.
FDA Fast Track DesignationThe company recently received Fast Track designation from FDA, which could expedite the approval process for its treatments.
Market ExpansionBRTX-100 has received IND clearance to move into a Phase 2 study for cervical spinal pain, potentially expanding its market and application.
Bears Say
Financial PerformanceThe company reported a net loss of ($4.8M) and revenue of $25k.
FundingThe company has sufficient funding into 2026 with $10.7M in cash.
BioRestorative Therapies News
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $1.21 and its highest was $2.55 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $12.29M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Nov 18, 2025 which is in 88 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on Aug 12, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.07.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Undervalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate is -0.36.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 7,978,117 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 2.041%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
BRTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and promising clinical trial results, particularly for BRTX-100, alongside a strong financial position with no debt. However, these positives were tempered by an increased operational loss and uncertainty in future revenue projections from the BioCosmeceutical business. On balance, the achievements and progress in clinical trials and regulatory pathways suggest a positive outlook.View all BRTX earnings summariesBRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(440.54% Upside)
Technical Analysis
Ownership Overview
15.94% Insiders
1.04% Mutual Funds
1.27% Other Institutional Investors
81.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---